John Horowitz
John Horowitz
E-mail megerősítve itt: adelaide.edu.au
Hivatkozott rá
Hivatkozott rá
Apixaban versus warfarin in patients with atrial fibrillation
CB Granger, JH Alexander, JJV McMurray, RD Lopes, EM Hylek, ...
New England Journal of Medicine 365 (11), 981-992, 2011
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
M Packer, PA Poole-Wilson, PW Armstrong, JGF Cleland, JD Horowitz, ...
Circulation 100 (23), 2312-2318, 1999
International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology
JR Ghadri, IS Wittstein, A Prasad, S Sharkey, K Dote, YJ Akashi, ...
European heart journal 39 (22), 2032-2046, 2018
Effects of a multidisciplinary, home-based intervention on planned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study
S Stewart, JE Marley, JD Horowitz
The Lancet 354 (9184), 1077-1083, 1999
International expert consensus document on Takotsubo syndrome (part II): diagnostic workup, outcome, and management
JR Ghadri, IS Wittstein, A Prasad, S Sharkey, K Dote, YJ Akashi, ...
European Heart Journal 39 (22), 2047-2062, 2018
Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care
S Stewart, S Pearson, JD Horowitz
Archives of Internal Medicine 158 (10), 1067-1072, 1998
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale
RD Lopes, JH Alexander, SM Al-Khatib, J Ansell, R Diaz, JD Easton, ...
American heart journal 159 (3), 331-339, 2010
Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial
Apex AMI Investigators
Jama 297 (1), 43-51, 2007
The coronary slow flow phenomenon–a new coronary microvascular disorder
JF Beltrame, SB Limaye, JD Horowitz
Cardiology 97 (4), 197-202, 2002
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina
E Topol, R Califf, F Van de Werf, R Diaz, E Paolasso, P Aylward, J Simes, ...
Circulation 97 (24), 2386-2395, 1998
Home-based intervention in congestive heart failure: long-term implications on readmission and survival
S Stewart, JD Horowitz
Circulation 105 (24), 2861-2866, 2002
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial
BF Uretsky, K Thygesen, PW Armstrong, JG Cleland, JD Horowitz, ...
Circulation 102 (6), 611-616, 2000
Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment
L Lee, R Campbell, M Scheuermann-Freestone, R Taylor, P Gunaruwan, ...
Circulation 112 (21), 3280-3288, 2005
Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure
S Stewart, AJ Vandenbroek, S Pearson, JD Horowitz
Archives of internal medicine 159 (3), 257-261, 1999
Metabolic manipulation in ischaemic heart disease, a novel approach to treatment
L Lee, J Horowitz, M Frenneaux
European heart journal 25 (8), 634-641, 2004
Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for …
L Wallentin, Z Hijazi, U Andersson, JH Alexander, R De Caterina, ...
Circulation 130 (21), 1847-1858, 2014
Systematic review and meta-analysis of incidence and correlates of recurrence of takotsubo cardiomyopathy
K Singh, K Carson, Z Usmani, G Sawhney, R Shah, J Horowitz
International journal of cardiology 174 (3), 696-701, 2014
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial
L Rydén, PW Armstrong, JGF Cleland, JD Horowitz, BM Massie, M Packer, ...
European heart journal 21 (23), 1967-1978, 2000
Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine.
JD Horowitz, EM Antman, BH Lorell, WH Barry, TW Smith
Circulation 68 (6), 1247-1253, 1983
Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon
JF Beltrame, SB Limaye, RD Wuttke, JD Horowitz
American heart journal 146 (1), 84-90, 2003
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20